1-(2-Methoxyphenyl)-4-(2,4,5-trichlorobenzenesulfonyl)piperazine

Catalog No. :
ACHJGE145
CAS No. :
669726-08-3
Molecular Formula :
C17H17Cl3N2O3S
Molecular Weight :
435.76

IUPAC Name:1-(2-methoxyphenyl)-4-((2,4,5-trichlorophenyl)sulfonyl)piperazine

1-(2-Methoxyphenyl)-4-(2,4,5-trichlorobenzenesulfonyl)piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$291.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(2-Methoxyphenyl)-4-(2,4,5-trichlorobenzenesulfonyl)piperazine
IUPAC Name1-(2-methoxyphenyl)-4-((2,4,5-trichlorophenyl)sulfonyl)piperazine
MDL No.MFCD00662041
Molecular FormulaC17H17Cl3N2O3S
Molecular Weight435.76
SMILESO=S(N1CCN(C2=CC=CC=C2OC)CC1)(C3=CC(Cl)=C(Cl)C=C3Cl)=O
InChI KeyHCKXVLPWPBJRDA-UHFFFAOYSA-N
Synonym2,4,5-TRICHLORO-1-((4-(2-METHOXYPHENYL)PIPERAZINYL)SULFONYL)BENZENE;1-(2-methoxyphenyl)-4-(2,4,5-trichlorobenzenesulfonyl)piperazine;Piperazine, 1-(2-methoxyphenyl)-4-[(2,4,5-trichlorophenyl)sulfonyl]-
CAS No.669726-08-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACHJGE145 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHJGE145 route product structure diagram
    ACHJGE145669726-08-3
Inquiry

2. ACHJGE145 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLTWX712 route compound structure diagram
    ACLTWX712578-57-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHJGE145 route product structure diagram
    ACHJGE145669726-08-3
Inquiry

Comments (0)